|
9th Annual Biomarkers Congress Announces Full Speaker List
Clicks:1114 Date:11/20/13
Oxford Global Conferences are proud to present the 9th Annual Biomarkers Congress, taking place on 25 & 26 February 2014 in Manchester.
This prestigious event will be held at Manchester United鈥檚 Old Trafford and Oxford Global is pleased to announce the full line up of speakers:
- Mark Curran, VP Immunology Biomarkers, Janssen
- Richard Buller, VP & Head, Clinical Development, Oncology, Pfizer
- Khusru Asadullah, VP and Head of Global Biomarkers, Bayer HealthCare
- John Burkhardt, VP, Preclinical Safety, Abbvie
- Bob Clay, VP Global Regulatory Affairs, Oncology, Infection and Personalised Healthcare, AstraZeneca
- Jörg Lippert, VP Clinical Pharmacometrics, Bayer
- Ken Rhodes, VP Neurology Discovery, Biogen Idec
- Iris Grossman, Global Head of Personalized Medicine & Pharmacogenomics, Teva
- Steven Pirie-Shepherd, Director Global R&D, Oncology Research Unit Pfizer Inc
- Yasuhiro Funahashi, Senior Director, Eisai
- Lakshmi Amaravadi, Senior Director Translational Medicine, BiogenIdec
- Ziad Taib, Statistical Science Director, Early Clinical Development, AstraZeneca
- Colin Orford, Global Head of Project Operations, Neurosciences PCU, Eisai
- Dianna Wu, Director, Clinical Flow Cytometry & Molecular Pathology, Merck
- Jens Wendland, Director and Head, Neuroscience Genetics, Pfizer
- Liz Harrington, Director, Translational Science Oncology, AstraZeneca
- Adam Platt, Diagnostic Development Director, AstraZeneca
- Christine Vitkauskas, Director, Companion Diagnostics, Merck
- Michael Letavic, Scientific Director, Janssen
- (Stream Chair) Edward Abrahams, President, Personalized Medicine Coalition
- Claudio Carini, Global Clinical Immunology and Biomarkers Lead, Pfizer
- Joachim Reischl, Head Global Biomarker Strategy and Development, Bayer
- Paul Cutler, Head of Mass Spectrometry, Roche
- Daniel Bradley, Head of Biomedical Imaging, Millennium: The Takeda Oncology Company
- Lore Gruenbaum, Head of Biomarker and Pathway Analysis, Virology, Roche
- Rainer Hillenbrand, Head of External Affairs Group BMD-MLA, Novartis
- Vitali Proutski, Head of the RDI Predictive Science Centre, AstraZeneca
- Alessandra Vitaliti Garami, Head of Molecular & Cellular Sciences, Biomarker Development, Novartis
- Serena Scollen, Head of Pain Genetics - Neusentis, Pharmatherapeutics Precision Medicine, Pfizer Neusentis
- Gerard B Fox, Head Of Imaging And Biochemical Biomarkers, Abbvie
- Tara Kieffer, Director, Clinical Biomarkers, Vertex
- Chris Harbron, Senior Principal Scientist, AstraZeneca
- Bernhard Reis, Principal Scientist Flow Cytometry, Roche
- Pia Davidsson, Principal Scientist DMPK, AstraZeneca
- Willem Talloen, Principal Statistician, Johnson & Johnson
- Elaine Kilgour, Principal Translational Scientist, AstraZeneca
- Sharon Moulis, Principal Scientist, Merrimack
- Nicholas Seneca, Personalized Healthcare Leader, Pharma - Product Development Neuroscience, F. Hoffmann-La Roche Ltd.
- Serafino Pantano, Global Correlative Science Lead, Novartis
- Sally Price, Associate Director, Pathology Sciences, Astrazeneca
- Iman Jilani, Associate Director, Biomarker Assay Specialist, Pfizer
- Peter Parker, Professor of Cancer Cell Biology, Kings College London
- Gerrit Meijer, Professor of Pathology, Chair of the Department of Pathology, VUmc
- Alain Van Gool, Professor, Senior Scientist Integrator Metabolic Health Research, TNO
- Stephen Roy Pennington, Professor of Proteomics, University College Dublin
- Richard O'Kennedy, Director, Biomedical Diagnostics Institute
- (Stream Chair) Bruce McManus, Professor, Department of Pathology and Laboratory Medicine, UBC, CEO, NCE CECR Centre of Excellence for Prevention of Organ Failure, Co-Director, Institute for Heart + Lung Health
- Sabrina Mattoli, Director, The Avail Biomedical Research Institute
- Anthony Rowe, Principal Scientist - External Innovation, Johnson & Johnson
- Maria Karpova, Lead Scientist Tissue Biobanking & Molecular Lab, Roche
- Magali Gibou, Senior Regulatory Affairs Manager, Global Regulatory Affairs, Transgene
- Sophie Wildsmith, Biomarker Key Service Area Manager, Strategic Outsourcing, Roche
- Kirsten Mundt, Senior Scientific Manager, Genentech
- Birgitte Søgaard, Divisional Director Clinical & Quantitative Pharmacology, Lundbeck
- Jean-Marie Bruey, Oncology Biomarker Development, Diagnostics, Genentech
- Philip De Decker, Senior Research Associate Pharmacology, Ablynx
- Daniel Forler, Alliance Management, Bayer
- Michael Cannarile, Biomarker & Experimental Medicine Leader, Roche
- Roberta Milone, Senior scientist, GSK
The congress will cover the latest advances in biomarker discovery, development and verification; focusing on breakthrough technologies and case studies from leading pharmaceutical organisations. The event also has dedicated clinical streams this year, looking at personalised medicine and companion diagnostics.
|
中文
